Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 11/2006

01-11-2006 | Review Article

Risperidone for the Treatment of Neuropsychiatric Features in Dementia

Authors: Professor Alistair Burns, Peter P. De Deyn

Published in: Drugs & Aging | Issue 11/2006

Login to get access

Abstract

Neuropsychiatric features of dementia are a common and significant burden on patients and their carers. Management usually involves a combination of pharmacological and non-pharmacological approaches. Antipsychotics are the cornerstone of treatment; among the atypical antipsychotics, risperidone is the most studied. Several trials have confirmed the efficacy of risperidone in the treatment of neuropsychiatric features in dementia, especially for agitation and psychosis. Recent concerns over an increased cerebrovascular adverse event profile and overall mortality with use of antipsychotics have emphasised the need for a risk-benefit analysis for individual demented patients being treated for neuropsychiatric features of their disease.
Literature
1.
Hendrie HC. Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr Psychiatry 1998; 6 (2 Suppl. 1): S3–18PubMed
2.
Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551–6PubMedCrossRef
3.
Hemels ME, Lanctot KL, Iskedjian M, et al. Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia. Drugs Aging 2001; 18: 527–50PubMedCrossRef
4.
Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. I: disorders of thought content. Br J Psychiatry 1990; 157: 72–94PubMedCrossRef
5.
Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14PubMedCrossRef
6.
Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996; 8Suppl. 3: 497–500PubMed
7.
Jeste DV, Finkel SI. Psychosis of Alzheimer’s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000; 8: 29–34PubMedCrossRef
8.
Donaldson C, Tarder N, Burns A. The impact of the symptoms of dementia on caregivers. Br J Psychiatry 1997; 170: 62–8PubMedCrossRef
9.
Burns A, Lawlor B, Craig S. Assessment scales in old age psychiatry. 2nd ed. London: Taylor & Francis, 2004
10.
Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987 May; 48(Suppl. 5): 9–15PubMed
11.
Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233–9PubMedCrossRef
12.
Cohen-Mansfield J. Conceptualization of agitation: results based on the Cohen-Mansfield agitation inventory and the agitation behavior mapping instrument. Int Psychogeriatr 1996; 8Suppl. 3: 309–15PubMed
13.
Brodaty H, Draper B, Saab D, et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry 2001; 16: 504–12PubMedCrossRef
14.
Ballard CG, Margallo-Lana M, Fossey J, et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry 2001; 62: 631–6PubMedCrossRef
15.
Tractenberg RE, Weiner MF, Thal LJ. Estimating the prevalence of agitation in community-dwelling persons with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2002; 14: 11–8PubMedCrossRef
16.
Haupt M, Kurz A, Janner M. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord 2000; 11: 147–52PubMedCrossRef
17.
Haupt M, Janner M, Ebeling S, et al. Presentation and stability of noncognitive symptom patterns in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 323–9PubMedCrossRef
18.
Rapoport MJ, van Reekum R, Freedman M, et al. Relationship of psychosis to aggression, apathy and function in dementia. Int J Geriatr Psychiatry 2001; 16: 123–30PubMedCrossRef
19.
Engelborghs S, Maertens K, Nagels G, et al. Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriatr Psychiatry 2005; 20: 1028–37PubMedCrossRef
20.
Lawton MP. Assessing quality of life in Alzheimer disease research. Alzheimer Dis Assoc Disord 1997; 11Suppl. 6: 91–9PubMed
21.
Tarrier N, Barrowclough C, Ward J, et al. Expressed emotion and attributions in the carers of patients with Alzheimer’s disease: the effect on carer burden. J Abnorm Psychol 2002; 111: 340–9PubMedCrossRef
22.
Tariot PN. Clinical effectiveness of atypical antipsychotics in dementia. J Clin Psychiatry 2004; 65Suppl. 11: 3–4PubMed
23.
24.
Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 2003; 51: 1305–17PubMedCrossRef
25.
Schneider LS, Pollock VE, Lyness SA. A meta analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63PubMed
26.
Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999; 7: 70–6PubMed
27.
Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000; 93: 457–62PubMed
28.
Zaudig M. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia. Drug Saf 2000; 23: 183–95PubMedCrossRef
29.
McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997; 314: 266–70PubMedCrossRef
30.
Lawlor B, Bhriain SN. Psychosis and behavioural symptoms of dementia: defining the role of neuroleptic interventions. Int J Geriatr Psychiatry 2001; 16Suppl. 1: S2–6PubMedCrossRef
31.
De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946–55PubMedCrossRef
32.
Liperoti R, Mor V, Lapane KL, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64: 1106–12PubMedCrossRef
33.
Alexopoulos GS, Jeste DV, Chung H, et al. The Expert Consensus Guideline Series: treatment of dementia and its behavioral disturbances. Postgrad Med Special Report 2005 Jan: 1–111
34.
Greve M, O’Connor D. A survey of Australian and New Zealand old age psychiatrists’ preferred medications to treat behavioural and psychological symptoms of dementia (BPSD). Int Psychogeriatr 2005; 17: 195–205PubMedCrossRef
35.
Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107–15PubMedCrossRef
36.
Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968–76PubMedCrossRef
37.
Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134–43PubMedCrossRef
38.
Schneider LS, Tariot PN, Lyketsos CG, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 2001; 9: 346–60PubMed
39.
Risperdal® (risperidone) [package insert]. Titusville (NJ): Janssen Pharmaceutica Products LP, 2005 May
40.
Chan WC, Lam LC, Choy CN, et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001; 16: 1156–62PubMedCrossRef
41.
Rainer MK, Masching AJ, Ertl MG, et al. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. J Clin Psychiatry 2001; 62: 894–900PubMedCrossRef
42.
Laks J, Engelhardt E, Marinho V, et al. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly. Arq Neuropsiquiatr 2001; 59: 859–64PubMedCrossRef
43.
Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998; 6: 127–35PubMed
44.
Frenchman IB, Prince T. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr 1997; 9: 431–5PubMedCrossRef
45.
Irizarry MC, Ghaemi SN, Lee-Cherry ER, et al. Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci 1999; 11: 336–42PubMed
46.
Yoon JS, Kim JM, Lee H, et al. Risperidone use in Korean patients with Alzheimer’s disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living. Hum Psychopharmacol 2003; 18: 627–33PubMedCrossRef
47.
Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150–5PubMedCrossRef
48.
De Deyn PP, Katz IR, Brodaty H, et al. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005; 107: 497–508PubMedCrossRef
49.
Mintzer J, Greenspan A, Caers I, et al. Risperidone in the treatment of psychosis of Alzheimer’s disease: results from a prospective clinical trial. Am J Geriatr Psychiatry 2006; 14: 280–91PubMedCrossRef
50.
Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167: 1269–70PubMed
51.
Suh GH, Son HG, Ju YS, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004; 12: 509–16PubMed
52.
De Deyn PP, Wirshing WC. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry 2001; 62Suppl. 21: 19–22PubMed
53.
Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997; 9: 65–8PubMedCrossRef
54.
Arriola E, Diago JI. Treatment with risperidone: positive impact on patients with BPSD and caregiver stress. Am J Geriatr Pharmacother 2005; 3: 8–16PubMedCrossRef
55.
Wancata J. Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. Int Psychogeriatr 2004; 16: 107–15PubMedCrossRef
56.
Schwalen S, Kurz A. Risperidone for the treatment of behavioural disorders in dementia. Nervenheilkunde 2002; 21: 208–13
57.
Shigenobu K, Ikeda M, Fukuhara R, et al. Reducing the burden of caring for Alzheimer’s disease through the amelioration of “delusions of theft” by drug therapy. Int J Geriatr Psychiatry 2002; 17: 211–7PubMedCrossRef
58.
Lane HY, Chang YC, Su MH, et al. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects. J Clin Psychopharmacol 2002; 22: 4–10PubMedCrossRef
59.
De Deyn PP, Katz IR. Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psychiatry 2000; 15Suppl. 1: S14–22PubMed
60.
Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65Suppl. 2: 5–99PubMed
61.
Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 464–70PubMedCrossRef
62.
Mion LC, Gregor S, Buettner M, et al. Falls in the rehabilitation setting: incidence and characteristics [published erratum appears in Rehabil Nurs 1989; 14: 133]. Rehabil Nurs 1989; 14: 17–22PubMedCrossRef
63.
Kiely DK, Kiel DP, Burrows AB, et al. Identifying nursing home residents at risk for falling. J Am Geriatr Soc 1998; 46: 551–5PubMed
64.
Marx MS, Cohen-Mansfield J, Werner P. Agitation and falls in institutionalized elderly persons. J Appl Gerontol 1990; 9: 106–17PubMedCrossRef
65.
Katz IR, Rupnow M, Kozma C, et al. Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial. Am J Geriatr Psychiatry 2004; 12: 499–508PubMed
66.
Martin H, Slyk MP, Deymann S, et al. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia [published erratum appears in J Am Med Dir Assoc 2003; 4: 290]. J Am Med Dir Assoc 2003; 4: 183–8PubMedCrossRef
67.
Greenspan A, Eerdekens M, Mahmoud R. Risk of cerebrovascular adverse events, including mortality, with risperidone in elderly patients. Int Psychogeriatr 2003; PB-041Suppl. 2: 261–2
68.
Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170: 1395PubMedCrossRef
69.
70.
71.
Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445PubMedCrossRef
72.
Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005; 17: 617–29PubMedCrossRef
73.
Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113–5PubMedCrossRef
74.
75.
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43PubMedCrossRef
76.
Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 2335–41PubMedCrossRef
77.
Katz IR, Brodaty H, De Deyn PP, et al. Risperidone in the treatment of psychosis of Alzheimer’s disease (PAD): a pooled analysis of 4 controlled trials. Poster presented at the annual scientific meeting of the American Geriatrics Society (AGS); 2005 May 11–15; Orlando (Florida), USA
78.
Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75–9PubMedCrossRef
79.
Metadata
Title
Risperidone for the Treatment of Neuropsychiatric Features in Dementia
Authors
Professor Alistair Burns
Peter P. De Deyn
Publication date
01-11-2006
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2006
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200623110-00004

Other articles of this Issue 11/2006

Drugs & Aging 11/2006 Go to the issue

Review Article

HIV and Aging

Review Article

Divalproex Sodium for the Treatment of Behavioural Problems Associated With Dementia in the Elderly

Leading Article

Anti-Tumour Necrosis Factor-α Therapy for Rheumatoid and Other Inflammatory Arthropathies

From the World Literature

Gerontology Forum

Therapy in Practice

Prescribing Antiepileptics for the Elderly

Original Research Article

Potentially Inappropriate Medication Prescribing for Elderly Outpatients in Emilia Romagna, Italy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits